Last reviewed 2026-04-22 · How we verify

Maxitrol®

Maxitrol is a topical ophthalmic combination that reduces inflammation and bacterial infection in the eye through corticosteroid and antibiotic action.

Maxitrol is a topical ophthalmic combination that reduces inflammation and bacterial infection in the eye through corticosteroid and antibiotic action. Used for Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof, Post-operative ocular inflammation and infection prophylaxis.

At a glance

Mechanism of action

Maxitrol combines dexamethasone (a potent corticosteroid) with neomycin and polymyxin B sulfates (broad-spectrum antibiotics). The dexamethasone suppresses inflammatory responses in ocular tissues, while the antibiotics provide coverage against common bacterial pathogens that may complicate inflammatory eye conditions.

Approved indications

• Steroid-responsive inflammatory ocular conditions with bacterial infection or risk thereof
• Post-operative ocular inflammation and infection prophylaxis

Common side effects

• Ocular irritation or discomfort
• Allergic contact dermatitis
• Secondary infection (if steroid masks infection)
• Elevated intraocular pressure (with prolonged use)

Key clinical trials

• Intravitreal Carboplatin for the Treatment of Participants With Recurrent or Refractory Intraocular Retinoblastoma (PHASE1)
• Efficacy Maxinom® And Maxitrol® in Reducing The Signs And Symptoms Of Acute Bacterial Conjunctivitis (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Maxitrol® CI brief — competitive landscape report
• Maxitrol® updates RSS · CI watch RSS
• St. Jude Children's Research Hospital portfolio CI